Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2013 December;55(4) > Panminerva Medica 2013 December;55(4):345-52

CURRENT ISSUEPANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6


eTOC

 

  PERCUTANEOUS CORONARY AND VASCULAR INTERVENTIONS


Panminerva Medica 2013 December;55(4):345-52

language: English

Innovations in drug-eluting stents

Nallu K., Yang D. C., Swaminathan R. V., Kim L. K., Feldman D.

Division of Cardiology, Weill Cornell Medical College New York Presbyterian Hospital New York, New York, USA


PDF  REPRINTS


Coronary artery disease affects patients worldwide and is a major cause of morbidity and mortality. Historically, the treatment approach for patients with coronary syndromes has been surgical. In the 1970s, percutaneous balloon angioplasty was introduced, leading to creation of a new field of interventional cardiology, which allowed a non-surgical minimally invasive approach to treat patients with coronary artery disease. However, the major limitations of balloon angioplasty were acute vessel closure and later restenosis. The introduction of bare metal stents and then drug-eluting stents (DES) revolutionized the practice of interventional cardiology and allowed for safe treatment of increasingly complex coronary artery lesions. Although drug-eluting coronary stents improve patient outcomes, they still have limitations. These limitations may arise from delayed endothelialization, local vessel hypersensitivity and endothelial dysfunction secondary to the drug elution, the durable polymer coating, or the stent scaffold. This comprehensive review will discuss the evolution of intracoronary stents from their introduction to current utilization of DES as well as future research on bioabsorbable stents and polymers.

top of page